| abstract |
The present invention provides methods for detecting susceptibility to metabolic syndrome. In particular, the presence of differences in at least one of the following genes; microsomal triglyceride transfer protein (MTP), fatty acid binding protein 2 (FABP2), annexin A5 (ANXA5), pyruvate dehydrogenase (lipoamide) alpha 2 (PDHA2), CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 1 (CDS 1), and glycerol kinase 2 (GK2) serves as a prognostic and diagnostic indicator of metabolic syndrome. Furthermore, metabolic syndrome can be treated by regulating the levels of MTP, FABP2, ANXA5, PDHA2, CDS1, and GK2. |